REPAIR-AMI Study: Bone Marrow Cells Improve Ejection Fraction, Reduce Remodeling
REFERENCE: Abstract: 3770
THORSTEN DILL, Kerckhoff-Klinik, Bad Nauheim
Progenitor cells from bone marrow, infused directly into coronary arteries of patients with ST-elevation myocardial infarction, have improved left ventricular function, reduced adverse cardiac remodeling and brought clinical benefits. These findings, measured by magnetic resonance imaging, come from a sub-study of the German REPAIR-AMI trial presented to the AHA sessions by Thorsten Dill. He answered questions from Peter Goodwin.
Heart Valves Grown from Amniotic Stem Cells to Repair Congenital Defects in Newborn Babies
REFERENCE: Abstract: 3445
SIMON HOERSTRUP, University Hospital, Zurich
Congenital heart malformations may soon be repaired by tissue-engineered valves, bio-engineered from stem cells and implanted into newborn babies. At the AHA sessions Simon Hoerstrup showed images of autologous human living heart valves formed by growing fetal amniotic stem cells on bio-degradable polymer scaffolds. He told Sarah Maxwell about their progress so far.
Anti-Thrombin Therapy for Acute Coronary Syndromes: Latest Study Results
Abstracts 3294 to 3303 AHA Oral Session, Wednesday
HARVEY WHITE, Green Lane Hospital, Auckland
Anti-thrombin therapies for patients with acute coronary syndromes were the subject of a session covering such new agents as fondaparinux and bivalirudin, and discussing therapy with heparins, aspirin, clopidogrel and glycoprotein 2b3a inhibitors. Harvey White co-chaired the session and told Peter Goodwin what he thought were some of the key clinical implications emerging.